Resverlogix secures $38 mln loan from Third Eye-led group
Calgary biotechnology company Resverlogix Corp (TSX: RVX) has received a commitment letter for a senior secured loan of about $38 million (US$30 million). The loan's provider is a syndicate led by Canadian alternative lending firm Third Eye Capital. Resverlogix said it also raised about $3.2 million in equity financing. The proceeds will support the company as it advances the Phase 3 clinical trial of its lead epigenetic therapeutic candidate. Resverlogix in December closed an $87 million private placement deal with China’s Shenzhen Hepalink Pharmaceutical Co Ltd.
11 April 2018•3 mins read
